
    
      This is a multi-center chart review registry on mRCC patients treated with axitinib. Primary
      objective is the dose adjustment. Secondary objectives are safety profile, objective response
      rate and progression free survival. Efficacy assessment will be based on investigators'
      judgment. Patients treated with 1st dose of axitinib between May 7, 2013 and June 30, 2015
      will be enrolled. The follow-up time is 12 months. Prior therapies should include sunitinib
      or interferon alpha.
    
  